OTCMKTS:GNMSF

Genmab A/S - GNMSF Stock Forecast, Price & News

$320.21

-1.99 (-0.62%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $320.20
▼
$325.82
50-Day Range: $312.20
▼
$385.95
52-Week Range: $260.25
▼
$479.99

Volume: 608 shs
Average Volume: 1,128 shs
Market Capitalization: $20.93 billion

P/E Ratio: 35.74
Dividend Yield: N/A
Price Target: N/A

About Genmab A/S (OTCMKTS:GNMSF) Stock

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Stock News Headlines

September 6, 2022 | finance.yahoo.com

Genmab to Present at Morgan Stanley 20th Annual Global Healthcare Conference

September 3, 2022 | finance.yahoo.com

Genmab A/S (GNMSF)

August 5, 2022 | finance.yahoo.com

Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates

August 5, 2022 | benzinga.com

BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

July 18, 2022 | finance.yahoo.com

AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022

June 13, 2022 | finance.yahoo.com

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial

June 11, 2022 | finance.yahoo.com

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

June 8, 2022 | finance.yahoo.com

Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference

May 11, 2022 | finance.yahoo.com

Genmab Announces Financial Results for the First Quarter of 2022

May 10, 2022 | finance.yahoo.com

Should You Buy Genmab (GMAB) Ahead of Earnings?

April 14, 2022 | finance.yahoo.com

Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study

February 16, 2022 | finance.yahoo.com

Genmab Publishes 2021 Annual Report

January 4, 2022 | finance.yahoo.com

Genmab and Synaffix Enter into License Agreement for ADC Technology

November 11, 2021 | markets.businessinsider.com

Genmab A-S earnings: here's what Wall Street expects

November 4, 2021 | finance.yahoo.com

Genmab Improves its 2021 Financial Guidance

November 4, 2021 | finance.yahoo.com

Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)

October 19, 2021 | finance.yahoo.com

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021

October 15, 2021 | finance.yahoo.com

Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy

October 14, 2021 | finance.yahoo.com

Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry

October 1, 2021 | finance.yahoo.com

Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)

September 20, 2021 | finance.yahoo.com

Genmab, Seagen, Lennar, SmileDirect See After-Hours Moves

September 20, 2021 | finance.yahoo.com

Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

August 27, 2021 | finance.yahoo.com

Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference

August 19, 2021 | seekingalpha.com

Genmab: Monoclonal Antibody Experts, Low Risk Business Model

August 18, 2021 | finance.yahoo.com

Genmab Stock Flashes Healthy RS Rating

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Company Calendar

Last Earnings: 8/10/2022
Today: 9/30/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:GNMSF
CUSIP: N/A
CIK: 1434265
Web: www.genmab.com
Phone: (457) 020-2728
Fax: 45-7020-2729
Employees: 1,212
Year Founded: 1999

Profitability

EPS (Most Recent Fiscal Year): $8.96
Trailing P/E Ratio: 35.74
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $478.57 million
Net Margins: 38.42%
Pretax Margin: 50.77%
Return on Equity: 17.12%
Return on Assets: 15.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.11
Quick Ratio: 13.11

Sales & Book Value

Annual Sales: $1.35 billion
Price / Sales: 15.51
Cash Flow: $7.83 per share
Price / Cash Flow: 40.89
Book Value: $54.02 per share
Price / Book: 5.93

Miscellaneous

Outstanding Shares: 65,370,000
Free Float: 64,363,000
Market Cap: $20.93 billion
Optionable: Not Optionable
Beta: 0.77

Social Links

Key Executives

Dr. Jan G.J. van de Winkel Ph.D. (Age 61)
Co-Founder, Pres & CEO
Comp: $2.35M

Mr. Anthony Pagano (Age 44)
Exec. VP & CFO
Comp: $697.16k

Mr. Anthony Mancini (Age 51)
Exec. VP & COO
Comp: $1.26M

Dr. Judith V. Klimovsky M.D. (Age 64)
Exec. VP & Chief Devel. Officer
Comp: $884.86k

Dr. Tahamtan Ahmadi (Age 49)
Exec. VP, Chief Medical Officer & Head of Experimental Medicines
Comp: $723.98k

Dr. Mijke Zachariasse Ph.D. (Age 48)
Director of Protein Production & Chemist and Non-Independent Director
Comp: $120.66k

Dr. Rima Bawarshi Nassar Ph.D. (Age 69)
VP, Head of Global Regulatory Affairs Oncology & Non-Independent Director
Comp: $107.26k

Mr. Peter Ros
Sr. Director of Fin. & Accounting

Mr. Andrew Carlsen
Sr. Director, VP & Head of Investor Relations

Ms. Birgitte Stephensen M.Sc. (Age 61)
Exec. VP & Chief Legal Officer

Key Competitors

View All Competitors

GNMSF Stock - Frequently Asked Questions

How have GNMSF shares performed in 2022?: Genmab A/S's stock was trading at $390.53 at the start of the year. Since then, GNMSF stock has decreased by 18.0% and is now trading at $320.21.
View the best growth stocks for 2022 here.
Are investors shorting Genmab A/S?: Genmab A/S saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 10,900 shares, a drop of 71.7% from the August 31st total of 38,500 shares. Based on an average daily trading volume, of 1,400 shares, the days-to-cover ratio is currently 7.8 days.
View Genmab A/S's Short Interest.
How were Genmab A/S's earnings last quarter?: Genmab A/S (OTCMKTS:GNMSF) announced its quarterly earnings data on Wednesday, August, 10th. The company reported $4.10 EPS for the quarter. The firm earned $452.87 million during the quarter. Genmab A/S had a trailing twelve-month return on equity of 17.12% and a net margin of 38.42%.
What is Genmab A/S's stock symbol?: Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How do I buy shares of Genmab A/S?: Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Genmab A/S's stock price today?: One share of GNMSF stock can currently be purchased for approximately $320.21.
How much money does Genmab A/S make?: Genmab A/S (OTCMKTS:GNMSF) has a market capitalization of $20.93 billion and generates $1.35 billion in revenue each year. The company earns $478.57 million in net income (profit) each year or $8.96 on an earnings per share basis.
How many employees does Genmab A/S have?: The company employs 1,212 workers across the globe.
How can I contact Genmab A/S?: Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728, via email at acn@genmab.com, or via fax at 45-7020-2729.

This page (OTCMKTS:GNMSF) was last updated on 9/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial